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Autoimmune diseases are associated with
numerous immunologic and pathologic
abnormalities, but the factors critical for
inducing disease are poorly understood
(1,2). Although genetic predisposition may
be a prerequisite for the development of
spontaneous systemic autoimmune diseases,
such as systemic lupus erythematosus (SLE)
(3), the incomplete concordance in SLE
twin studies (4) suggests that exogenous or
environmental factors are also important.
Some of the best examples of systemic
autoimmune disease triggered by environ-
mental agents come from chemical-induced
autoimmunity, and have been described
both in humans (5,6) and in animal models
(5,7,8). In addition, studies using murine
models of lupus have shown that a variety of
other exogenous agents can accelerate the
onset of autoimmunity in genetically predis-
posed hosts (9–12); however, no speciﬁc fac-
tor has been documented to play a vital role
in idiopathic SLE.
Delineation of the role that environmen-
tal agents play in accelerating and/or exacer-
bating human autoimmune disease generally
has not considered the fact that a subset of
individuals may be particularly sensitive
because of genetic predisposition. Although
associations between environmental expo-
sure and certain autoimmune diseases have
been identified in epidemiologic studies
(6,13), these studies have not identified
those at risk. In addition, the genes that pre-
dispose to autoimmunity and their responses
to environmental exposures have yet to be
determined. Therefore, it has not been possi-
ble to test in humans whether genetic predis-
position to spontaneous autoimmunity
increases the sensitivity to environmental
agents. The availability of animal models
that spontaneously develop systemic autoim-
munity provides an alternative approach to
studying this question. Moreover, due to
derivation from different genetic back-
grounds, murine models of SLE manifest
both quantitative and qualitative differences
in disease expression that can be exploited
(14,15). 
Certain heavy metals, such as mercury,
are potent environmental agents toxic to the
immune system which can provoke not only
immunosuppressive but also immunostimu-
latory effects in many species, including
humans and rodents (reviewed in 8 and 16).
Studies with nonautoimmune-prone animal
models suggest that the immunoactivating
properties of mercury can be divided into
three major pathologic sequelae: lympho-
proliferation, hypergammaglobulinemia,
and the development of systemic autoim-
munity manifested as production of
autoantibody and immune-complex disease
(8,15). Elicitation of these pathologic fea-
tures depends on genetic background, with
lymphadenopathy occurring in most
strains, whereas autoimmunity—which in
nonautoimmune-prone strains is controlled
largely by the MHC gene—is more
restricted (17,18). Exposure to mercury of
autoimmune-prone MRL-+/+ and NZBWF1
mice accelerates autoimmunity in a strain-
speciﬁc manner, with the most severe mani-
festations occurring in the NZBWF1 (19).
Contrastingly, MRL-lpr mice, which are
deficient for the Fas apoptosis-promoting
gene and manifest more severe disease,
exhibited little acceleration of humoral
autoimmunity, suggesting that strains with
highly accelerated disease may be less sensi-
tive to environmental exposure. In addition,
comparison with the H-2 compatible
nonautoimmune-prone AKR mice indicated
that both MHC and non-MHC genes con-
tributed to acceleration of disease expression
in the MRL-+/+. In these studies, lupus-
prone strains expressed MHC haplotypes
that predispose to HgIA. Therefore, the
extent to which susceptibility was due to
HgIA or to underlying non-MHC suscepti-
bility genes could not be clearly delineated. 
In this study, we examined the inﬂuence
of mercury exposure and dosage on expres-
sion of autoimmunity in the lupus-prone
BXSB mice. In this strain, severe accelerated
autoimmunity with early mortality occurs in
males due to the Y-chromosome linked gene
Yaa, whereas females develop a delayed and
much milder form of disease (3,15).
Importantly, the MHC haplotype of this
strain (H-2b) is considered resistant to
HgCl2 since other strains with this haplo-
type, including the C57BL/6, which was
used as the control in this study, are much
less susceptible to HgIA than mice of other-
wise similar backgrounds expressing s, k, or
d haplotypes (8,17,18). Mercury exposure
accelerated autoimmunity in BXSB mice
consistent with idiopathic rather than HgIA
disease based on the predominant types of
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The diverse genetic backgrounds of lupus-prone murine models, which produce both quantitative
and qualitative differences in disease expression, may be a valuable resource for studying the inﬂu-
ence of environmental exposure on autoimmune disease in sensitive populations. We tested this
premise by exposing autoimmune-prone BXSB and the nonautoimmune C57BL/6 mice to the
heavy metal mercury. Although both strains express a nonsusceptible H-2 haplotype, exposure to
mercury accelerated systemic autoimmunity in both male and female BXSB mice, whereas the
C57BL/6 mice were resistant. The subclasses of antichromatin antibodies elicited in BXSB mice
by mercury exposure were more consistent with the predominant Th1-type response of idiopathic
disease than with the Th2-type response found in mercury-induced autoimmunity (HgIA). The
appearance and magnitude of both humoral and cellular features of systemic autoimmunity corre-
lated with the mercury dose. Furthermore, environmentally relevant tissue levels of mercury were
associated with exacerbated systemic autoimmunity. These studies demonstrate that xenobiotic
exposure can accelerate spontaneous systemic autoimmunity, and they support the possibility that
low-level xenobiotic exposure enhances susceptibility to systemic autoimmunity in genetically sus-
ceptible individuals. Key words: autoantibodies, autoimmunity, in vivo animal models, lupus,
rodent. Environ Health Perspect 109:27–33 (2001). [Online 30 November 2000]
http://ehpnet1.niehs.nih.gov/docs/2001/109p27-33pollard/abstract.htmlIgG autoantibody subclasses detected.
Dose–response studies suggested that envi-
ronmentally relevant tissue levels of mercury
were able to exacerbate systemic autoimmu-
nity. These studies support the concept that
low-level xenobiotic exposure can accelerate
idiopathic systemic autoimmunity in geneti-
cally susceptible hosts.
Materials and Methods
Mice. Male and female BXSB (H-2b), and
female C57BL/6 (H-2b) mice were obtained
from The Scripps Research Institute Animal
Colony (La Jolla, CA) and maintained under
speciﬁc pathogen-free conditions. All experi-
mental procedures using animals followed
the guidelines set down in the National
Institutes of Health Guide for the Care and
Use of Laboratory Animals (1996).
Treatment of mice. In short-term expo-
sure studies, groups of up to eight 4-week-
old mice were injected subcutaneously (sc)
twice per week for 4 weeks with 100 µL PBS
containing 40 µg HgCl2, or PBS alone. Mice
were bled for sera before the first injection
and at sacrifice on day 30. Autopsies were
performed as described previously (20).
Samples of kidney and spleen were taken for
analysis of immune-complex deposition as
described previously (see below).
Separate experiments were performed to
examine for the persistence of autoimmunity
following mercury exposure. Eight-week-old
female BXSB and C57BL/6 mice were
treated for 4 weeks with either HgCl2 or
PBS and then bled at 2-week intervals to
assess autoantibody levels. At sacriﬁce, sam-
ples of kidney and spleen were obtained and
proteinuria was determined.
To examine the effect of HgCl2 dose on
acceleration of autoimmunity, we injected
groups of 8-week-old female BXSB mice
with 40, 4, 0.4, or 0.04 µg HgCl2 in PBS
twice per week for 11 months. Control mice
received PBS. Mice were monitored for dis-
ease as above. Samples of kidney were also
analyzed for mercury content as described
previously (21). 
Detection of serum antibodies. ANA was
detected as described previously (22) using
HEp-2 cell slides (Bion Enterprises, Park
Ridge, IL). Sera were diluted 100-fold in
PBS containing 0.5% bovine serum albu-
min (BSA), 0.1% BGG, 0.001% gelatin,
and 0.05% Tween 20 before assay. Goat
anti-mouse IgG-FITC (Caltag Laboratories,
San Francisco, CA), diluted 100-fold in
PBS containing 0.5% BGG, 0.1% BSA,
and 0.05% Tween 20, was used as detecting
reagent. Antifibrillarin (nucleolar) mono-
clonal antibody 72B9 (23) was used as posi-
tive control.
Antichromatin antibodies were detected
by ELISA (24). Sera were diluted 100-fold
before assay, and chromatin-bound antibodies
were detected with HRP-conjugated goat
anti-mouse IgG (Caltag Laboratories),
diluted 2,000-fold. Antichromatin mono-
clonal antibody 1D12 (25) was used as
positive control. The IgG subclass of
antichromatin antibodies in female BXSB
mice was also determined by ELISA, using
serum dilutions of 1/100–1/400 and a
saturating (1/1,000) dilution of subclass
detecting reagent. Horseradish peroxidase
(HRP)-conjugated anti-IgG1 and IgG2b
were from Caltag Laboratories, anti-IgG2aa+b
was from Pharmingen (San Diego, CA), and
anti-IgG3 was from Southern Biotechnology
Associates (Birmingham, AL).
Serum immunoglobulin quantitation.
Serum IgG, IgG1, and IgG2a levels were
quantified by ELISA (26,27). ELISA plates
were coated with 200 µL 2 µg/mL goat anti-
mouse kappa light chain antibody (Caltag
Laboratories) diluted in phosphate-buffered
saline (PBS) and incubated overnight at 4°C.
Plates were postcoated for 1 hr with 0.1%
gelatin in PBS followed by 3 washes with
PBS-0.05% Tween 20. Sera were diluted in
serum diluent (26). A standard curve was
generated by serial dilutions of polyclonal
mouse reference serum containing predeter-
mined levels of Ig isotypes (The Binding
Site, Birmingham, UK). Diluted sera were
incubated in duplicate while shaking for 2.5
hr followed by 3 washes with PBS-0.05%
Tween 20. HRP-conjugated goat anti-
mouse IgG, or IgG1 antibodies (Caltag
Laboratories) were diluted in anti-Ig diluent
(26) and incubated with shaking for 90 min.
After 3 washes with PBS-0.05% Tween 20
and 4 washes with PBS, ABTS substrate
solution was added and the optical density
(OD) read at 405 nm. Determination of
IgG2a in sera from BXSB and C57BL/6
mice required use of reagents speciﬁc for the
b allotype of IgG2a (27). Serum IgG, IgG1,
and IgG2a concentrations were calculated by
extrapolation from the linear portion of
standard curves. 
Tissue immune-complex deposits. A 2–3
mm thick section of the kidney and spleen
were snap-frozen in isopentane-CO2 and
examined by direct immunofluorescence as
described previously (28). Briefly, 4–5 µm
thick cryostat sections were ﬁxed in ethanol
and incubated with doubling dilutions of
FITC-conjugated goat antibodies to IgG
(gamma chain specific) and C3 (Southern
Biotechnology Associates). The end-point
titer of the immune deposits was deﬁned as
the highest dilution of antibody at which
speciﬁc ﬂuorescence could be detected. The
presence of granular deposits in small and
medium-sized arteries was also examined.
The slides were examined under blinded
conditions.
Light microscopy. A 2–3 mm thick sec-
tion of the kidney was immersed in
Histochoice (Amresco, Solon, OH), and
embedded in paraplast, and 1–2 µm sections
were cut. The sections were stained with
periodic acid–Schiff (PAS) reagent and with
periodic-acid-silver-methenamine. The types
of glomerular pathology were determined,
and the degree of endocapillary cell hyper-
plasia was scored for each animal as follows:
0 = normal; 0.5 = just detectable alteration;
1 = slight; 2 = moderate; 3 = strong; and 4 =
maximal. Slides were examined without
knowledge of treatment or other results.
Urinary protein. Proteinuria was mea-
sured by Chemstrip 2 GP test strips as
described by the manufacturer (Boehringer
Mannheim Diagnostics, Indianapolis, IN).
To compare results between groups, the mil-
ligram protein per deciliter scale was graded
(0 = negative, 1 = trace, 2 = 30, 3 = 100, 4 =
500 mg/dL). Intermediate values were
graded at 0.5 units above the lower value
(i.e., 1.5 = trace to 30 mg/dL). In the mer-
cury dose–response study, proteinuria was
measured using the Bradford assay (Pierce,
Rockford, IL) with BSA as the protein 
standard.
Flow cytometry analysis of peripheral
blood lymphocytes (PBL). Flow cytometry
procedures were performed as described pre-
viously (29). Brieﬂy, PBL were stained with
the following antibodies (Pharmingen, La
Jolla, CA): APC-conjugated anti-mouse
CD11b, FITC-conjugated anti-CD3e,
cychrome-conjugated anti-CD45R/B220,
and PE-conjugated anti-I-Ab antibodies. The
anti-CD16/CD32 (Fcγ III/IIR) antibody,
2.4G2, was also added to block nonspeciﬁc
FcR binding. Data were acquired on the
FACSVantageTMSE and analyzed using
CELLQuest (Becton-Dickinson, Sunnyvale,
CA). Ten to twenty thousand events were
collected, and live-gated cells, based on for-
ward and side scatter characteristics, were
examined. 
Statistical analysis. Unless otherwise
noted, all data are expressed as mean ± 1SD.
Groups were compared by unpaired t-test,
single-factor analysis of variance, Mann-
Whitney U test, or Fisher’s Exact Test as
appropriate. Comparisons are of HgCl2-
treated mice with PBS-treated animals; p <
0.05 was considered signiﬁcant.
Results
Effects of short-term mercury exposure on 4-
week-old male BXSB mice. Although male
BXSB mice are highly susceptible to SLE, 4
weeks of mercury exposure signiﬁcantly ele-
vated levels of serum IgG and IgG1 and
IgG2a subclasses, compared to PBS control
animals (Table 1). Antibodies to nuclear
antigens (ANA) consisting of a dense ﬁne to
Articles • Pollard et al.
28 VOLUME 109 | NUMBER 1 | January 2001 • Environmental Health Perspectiveshomogeneous nuclear speckling of interphase
cells and metaphase chromosomes was found
in 88% of male mice exposed to HgCl2,
while pretreatment bleeds as well as PBS-
treated mice had less frequent ANA
responses (range 0–25%). Similarly, levels of
antichromatin antibodies in HgCl2-exposed
male mice were elevated above those found
in the PBS group (Table 1).
When compared to PBS-treated animals,
HgCl2-treated male BXSB mice had increased
organ wet weight for spleen and the draining
cervical lymph nodes but not the mesenteric
lymph nodes (Table 2). Glomerular deposits,
localized to the mesangium, were observed in
both HgCl2-exposed and PBS-control ani-
mals, with mean titers higher in the mercury
group (Table 2). This, however, did not reach
statistical signiﬁcance because of large varia-
tions in individual titers. Nevertheless, com-
pared to PBS controls, mercury-exposed male
BXSB mice showed significant increases in
endocapillary cells as observed by light
microscopy (1.62 ± 0.44 vs. 0.56 ± 0.050; p
< 0.01) (Figure 1). Glomerular basement
membranes were normal and there was no
inflammation. Interestingly, although non-
glomerular deposits to the kidney vessel wall
are typically seen in HgIA, they were absent
in the mercury-exposed male BXSB mice.
This suggests that the systemic autoimmu-
nity induced in male BXSB mice by HgCl2
was more consistent with spontaneous lupus
than with HgIA. 
Effects of short-term mercury exposure
on 4-week-old female BXSB mice. Female
BXSB mice are considerably less susceptible
to SLE than their male counterparts, and
develop mild SLE in late life. Nonetheless,
mercury-exposed female BXSB mice also
had elevations of serum IgG, IgG1, and
IgG2a compared to PBS controls, although
levels were lower than those in male HgCl2-
treated mice (Table 1). Similar to male mice,
88% of females exposed to HgCl2 developed
ANAs that consisted of dense ﬁne to homo-
geneous nuclear speckling of interphase cells
and metaphase chromosomes (Table 1).
PBS-treated mice, as well as all pretreatment
bleeds, had less frequent ANA responses
(range 0–29%). Although two HgCl2-
exposed female mice had elevated antichro-
matin antibodies, the response of this group
was not statistically different from the PBS-
treated group (Table 1). 
HgCl2-treated female BXSB mice had
greater organ wet weight for spleen and cervi-
cal lymph nodes but not mesenteric lymph
nodes, compared to PBS treated animals
(Table 2). The two HgCl2-treated female
mice with elevated antichromatin antibodies
also had low titers of IgG deposits in the
mesangium, whereas the remaining six
HgCl2-treated mice as well as all mice given
PBS showed no IgG deposits (Table 2). The
titers of glomerular C3 deposits were similar
between the two groups. Histologic examina-
tion revealed increased glomerular endocapil-
lary cells in HgCl2-treated mice (2.38 ± 0.92
vs. 1.29 ± 0.57, p < 0.05), but basement
membranes were normal and there was no
inﬂammation. Vessel wall deposits were not
found in the kidney or spleen in either group.
Effect of short-term mercury exposure on
nonautoimmune-prone 4-week-old female
C57BL/6 mice. Compared to PBS-treated
mice, mercury-exposed C57BL/6 mice
developed hypergammaglobulinemia with
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Table 1. Immunoglobulin levels and autoantibodies in BXSB mice following HgCl2 exposure.a,b
Immunoglobulin level
IgG IgG1 IgG2a ANA Antichromatin
Sex No. Treatment (mg/mL) (mg/mL) (µg/mL) (pos/no.) Ab
Male 8 Pre PBS 2.5 ± 1.3 0.03 ± 0.10 77 ± 59 1/8 0.00 ± 0.00
Post 4.7 ± 3.6 0.28 ± 0.16 126 ± 60 1/8 0.26 ± 0.31
8 Pre HgCl2 1.9 ± 0.9 0.20 ± 0.11 58 ± 36 0/8 0.13 ± 0.19
Post 13.9 ± 3.0## 3.34 ± 0.59## 802 ± 133## 7/8 0.98 ± 0.57**
Female 8 Pre PBS 1.9 ± 2.0 0.19 ± 0.08 17 ± 6 1/7 0.01 ± 0.01
Post 5.2 ± 2.6 0.24 ± 0.05 34 ± 14 2/7 0.03 ± 0.03
8 Pre HgCl2 1.5 ± 0.7 0.13 ± 0.06 10 ± 9 1/8 0.12 ± 0.51
Post 6.7 ± 1.8* 2.17 ± 0.42## 96 ± 45# 7/8 0.60 ± 0.93
Abbreviation: pos/no., number positive/total number. p-Values are from comparison of mercury-treated groups with PBS-
treated group.
aMice were 4 weeks old at the beginning of the experiment. bValues are given as mean ± 1SD. *p < 0.05. **p < 0.01. #p <
0.005. ##p < 0.0001. 
Table 2. Pathologic changes in BXSB mice following HgCl2 exposure.a
Organ wet weight (mg) Kidney immunopathologyb,c
Cervical Mesenteric Glomerular Vessel
Sex No. Treatment Spleen LN LN IgC C3 IgG C3
Male 8 PBS 116 ± 5 24 ± 3 47 ± 1 151 830 0 0
8 HgCl2 237 ± 27† 108 ± 13## 61 ± 9 2,348 3,620 0 0
Female 7 PBS 62 ± 3 32 ± 3 52 ± 6 0 476 0 0
8 HgCl2 79 ± 3d# 49 ± 3## 47 ± 2 1 453 0 0
LN, lymph node. p-Values are from comparison of mercury-treated groups with PBS-treated group. 
aMice were 4 weeks old at the beginning of the experiment. bImmunopathology data is given as geometric mean. cData
are expressed as the reciprocal titer. dData from seven animals. †p < 0.001. #p < 0.005. ##p < 0.0001.
Figure 1. Representative glomerular light microscopy of male and female BXSB mice. Four-week-old mice
were treated with PBS (A, C) or HgCl2 (B, D) for 4 weeks. Endocapillary cell proliferation was scored as
described in “Materials and Methods.” The kidney in (A) was scored as 0 and (B) as 2+. The kidney in (C)
was scored as 1+ and (D) as 3+. Magniﬁcation x800.elevations in IgG, IgG1, and IgG2a and a
dense ﬁne speckled ANA pattern (Table 3).
However, the mean antichromatin antibody
level was not elevated (Table 3). One PBS-
treated mouse had an elevated antichromatin
response (OD405 = 3.1), suggesting a low
penetrance susceptibility to antichromatin
autoantibody production in this strain.
None of the mercury-treated C57BL/6 mice
had increased deposition of immunoglobulin
or complement (C3) in the kidney or spleen,
and histology by light microscopy was unre-
markable (data not shown). The lack of ele-
vated antichromatin antibodies and kidney
pathology in mercury-exposed C57BL/6
mice indicates that non-MHC genes are the
major contributors to the HgCl2-induced
responses in BXSB mice.
Transient HgCl2 exposure in 8-week-old
female BXSB mice. To study the long-term
effects of HgCl2 following transient expo-
sure, we gave 8-week-old female BXSB mice
HgCl2 or PBS for 1 month and then fol-
lowed them for 32 weeks without further
treatment. Mice were tested for autoantibod-
ies at 2-week intervals and examined for
immunopathology at the end of the experi-
ment. C57BL/6 mice were treated similarly
and tested only for autoantibodies because
previous studies have already established that
immunohistologic abnormalities do not
develop in this strain [see above (17,18)].
The antichromatin response in HgCl2-
treated BXSB mice was signiﬁcantly elevated
above that of PBS-treated mice up to 14
weeks after treatment (Figure 2), following
which PBS-treated mice began to develop
antichromatin antibodies. In contrast, HgCl2-
treated C57BL/6 mice had low levels of
antichromatin Ab, not signiﬁcantly different
from their PBS controls (data not shown).
Compared to 4-week-old female BXSB
(Table 1), older 8-week-old female mice were
more susceptible to HgCl2-induced accelera-
tion of antichromatin antibodies. 
Histologic examination of kidneys
revealed titers of glomerular IgG and C3
deposits that were higher in HgCl2-treated
mice but varied widely among individual
animals (Table 4). Three of the control mice
showed a combination of granular capillary
wall and mesangial IgG staining, whereas the
remaining four had only mesangial staining.
Of the HgCl2-treated mice, one showed a
combined granular capillary wall and mesan-
gial IgG staining, two showed only granular
capillary wall staining, and the remaining
ﬁve mice had only mesangial staining. Mice
with staining of the capillary loops, with or
without concomitant mesangial staining,
showed endocapillary cell hyperplasia. Most
animals also had a moderate thickening and
irregularity of the glomerular basement mem-
brane. Mesangial deposits were associated
only with slight endocapillary cell hyperpla-
sia. Four of the HgCl2-treated but none of
the PBS-treated mice had deposits of IgG in
kidney vessels. The titer and frequency of
immunoglobulin and complement deposits
in the spleen was also higher in HgCl2-
treated mice, with seven of eight having IgG
deposits and six of those seven having C3
deposits, whereas only three PBS mice had
low titer deposits of IgG and C3 in splenic
vessels. The increased titers and frequency of
immune reactants in the tissues of HgCl2-
treated mice pointed to the development of
more severe disease in these animals com-
pared to PBS-treated mice. Consistent with
this was the finding that three of the seven
HgCl2-treated mice tested had > 30 mg/dL
protein in their urine, whereas all five PBS
mice tested had ≤ 30 mg/dL (p < 0.05;
Table 4). Thus, compared to PBS controls,
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Table 3. Immunoglobulin levels and autoantibodies in female C57BL/6 mice following HgCl2 exposure.a,b
Immunoglobulin level
IgG IgG1 IgG2a ANA Antichromatin
No. Treatment (mg/mL) (mg/mL) (µg/mL) (pos/no.) Ab
8 Pre PBS 1.07 ± 0.37 0.15 ± 0.09 4.2 ± 2.1 0/8 0.00 ± 0.00
Post 2.77 ± 0.71 0.06 ± 0.42 13.6 ± 15.8 1/8 0.40 ± 1.11
8 Pre HgCl2 1.49 ± 0.51 0.28 ± 0.26 3.2 ± 1.8 0/8 0.00 ± 0.00
Post 7.68 ± 1.69§ 1.62 ± 0.33† 73.5 ± 35.4† 8/8 0.17 ± 0.23
Abbreviation: pos/no., number positive/total number. p-Values are from comparison of mercury-treated groups with PBS-
treated group. 
aMice were 4 weeks old at the beginning of the experiment. bValues are given as mean ± 1SD. §p < 0.02. †p < 0.001.
Figure 2. Comparison of the magnitude and persistence of antichromatin antibodies in BXSB after expo-
sure to mercury. Female mice were injected with either HgCl2 or PBS for 4 weeks and then bled at 2-week
intervals. Serum antichromatin antibodies were determined by ELISA. Different symbols denote individual
mice. Significant differences were found between the two groups of BXSB mice at 4 (p < 0.01), 6 (p <
0.005), 8 (p < 0.01), 10 (p < 0.01), 12 (p < 0.025), and 14 (p < 0.038) weeks. 
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Table 4. Pathologic changes in 40-week-old female BXSB mice following HgCl2 exposure.
Kidney immunopathologya Spleen immunopathologya
Glomerular Vessel Vessel Urinary
No. Treatment IgG C3 IgG C3 IgG C3 protein
7b PBS 263 707 0 0 3 2 1.3 ± 0.5c
8 HgCl2 293 3,044 5 1 180§ 43 2.4 ± 1.0*d
p-Values are from comparison of mercury-treated groups with PBS-treated groups. 
aImmunopathology data are given as geometric mean, and data are expressed as the reciprocal titer. bOne animal died
during bleeding. cData from ﬁve animals. dData from seven animals.*p < 0.05. §p < 0.02. 
Figure 3. IgG subclass of antichromatin antibodies in BXSB mice with spontaneous and HgCl2-acceler-
ated autoimmunity. Sera from mice at 4–6 (A) or 32 (B) weeks after the start of HgCl2 or PBS treatment
were analyzed for IgG subclass antichromatin antibodies by ELISA. The percent contribution of each sub-
class was determined from the sum of the OD405 values for the individual subclasses. 
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IgG subclasses of antichromatin antibod-
ies in BXSB mice with idiopathic and xeno-
biotic accelerated autoimmunity. HgIA is
associated with a Th2-like response charac-
terized by increases predominantly in
autoantibodies of the IgG1 subclass (30).
HgCl2 also has been shown to promote devi-
ations from Th1 to Th2 predominance in
several autoimmune diseases (27). In con-
trast, the spontaneous antichromatin
response in BXSB mice is mainly of the
IgG2a and IgG2b subclasses (31) due to the
predominant Th1-like cytokine response in
this strain (32). Thus, the IgG isotype
autoAb levels of mercury-treated BXSB mice
might indicate whether the accelerated
autoimmunity resulted from the sponta-
neous (Th1) or HgIA (Th2) types of
response. Sera from the long-term study of
female BXSB mice treated transiently with
HgCl2 were examined for antichromatin
IgG subclass levels. Immediately after 4
weeks of mercury exposure, all ﬁve antichro-
matin antibody-positive mice had subclasses
that were predominantly of the IgG2a and
IgG2b isotypes (Figure 3). Except for an
IgG1 response in one mouse (No. 16), there
were few antichromatin antibodies of the
IgG1 and IgG3 subclasses. Thirty-two weeks
after treatment began, the antichromatin IgG
subclasses in PBS- and HgCl2-treated mice
were very similar, consisting in particular of
IgG2b as well as IgG2a subclasses. One PBS
mouse (No. 3) had a strong IgG3 response,
while HgCl2-treated mouse No. 16 had
retained its IgG1 and IgG2a responses and
increased its IgG2b response (Figure 3).
Effects of long-term exposure and lower
doses of HgCl2 on the development of
autoimmunity in female BXSB mice.
Although the dose of HgCl2 used in the
above studies could accelerate autoimmunity
in BXSB mice, the resulting tissue levels of
mercury would be greater than that found in
humans exposed to environmental levels of
mercury (21,33,34). To determine whether
lower levels of HgCl2 exposure could also
trigger autoimmune disease in female BXSB
mice, we gave groups of 8-week-old animals
either 40, 4, 0.4, or 0.04 µg HgCl2 twice per
week for almost 11 months. For mice given
the highest dose of 40 µg, all succumbed or
were moribund by 24 weeks of treatment
after becoming severely cachexic. One
mouse each in the 4 µg and 0.4 µg groups
died at 31 and 38 weeks, respectively.
Survival of mice in the 0.04 µg and PBS
groups was not affected by treatment. 
The antichromatin Ab response of
female BXSB mice was clearly induced by
exposure to HgCl2 in a dose-dependent
manner even with doses as low as 0.4 µg.
Elevated levels were detected ﬁrst in the 40
µg HgCl2 group as soon as 4 weeks after the
start of treatment and then 4 weeks later in
the 4 µg HgCl2 group (Figure 4). After
16–20 weeks of treatment, the 0.4 µg HgCl2
group developed high levels of antichro-
matin Ab, equivalent to those in the 40 and
4 µg HgCl2 groups. Antichromatin Ab levels
subsequently remained elevated in these
three groups for the remainder of the experi-
ment. Even the lowest 0.04 µg HgCl2 group
tended to have higher antichromatin Ab lev-
els than the PBS control at the end of the
treatment period, but the levels did not
reach those of groups given higher doses. 
The accelerated autoimmune disease in
male BXSB mice is associated with increases
in memory/effector phenotype T cells and
Mac-1 positive macrophages in the peripheral
blood that may play a role in disease patho-
genesis (14). When peripheral blood cells
were examined after 32 weeks of HgCl2
exposure, no changes were found in the per-
centage of peripheral blood mononuclear
cell (PBMC) CD4+ T cells or B (B220+)
cells (Table 5). However, mice receiving 4
µg HgCl2 had increases in activated pheno-
type (CD44hi) CD4+ T cells (p < 0.005) and
an increase in percentage of CD62L (Mel-
14)lo CD4+ T cells, particularly when com-
pared to the 0.04 µg HgCl2 group (p <
0.025). Mice receiving 4 µg HgCl2 also had
an increased percentage of Mac-1 (CD11b)
positive cells (p < 0.02). These increases in
memory/effector and Mac-1 positive cells
were less pronounced than that typically
observed in male BXSB mice, and these spe-
cific manifestations may depend largely on
the presence of the Yaa gene. Mice receiving
0.4 µg HgCl2 had no statistically signiﬁcant
increases in PBMC phenotypic markers
(Table 5). 
We also examined urinary protein after
32 weeks of treatment. Mice in the 4 µg and
0.4 µg groups had increased proteinuria
compared with PBS controls (p < 0.05),
whereas mice receiving 0.04 µg HgCl2 had
similar levels (Table 5). After 38 weeks of
treatment, the surviving mice were sacriﬁced
and kidney pathology and mercury levels
were examined. Mice in the 4 µg group had
the most severe glomerular changes (average
score ± SE, 2.2 ± 0.6); this was the only
group that differed significantly from the
PBS controls (score 0.6 ± 0.1, p = 0.03;
Figure 5). The two mice from the 40 ug
group that were sacrificed at 20 and 23
weeks had only mild changes (score 1.3 ±
0.3), suggesting that the early mortality from
mercury toxicity was probably unrelated to
glomerulonephritis. Interestingly, this was
the only group that developed vascular
deposits of IgG, a finding characteristically
observed with HgIA. Mice in the 0.4 and
0.04 µg groups had glomerular changes simi-
lar to those in the PBS group (scores of 0.8
and 0.6, respectively). Mercury levels in the
kidney (Table 6), which reflects the overall
exposure of the animal, were significantly
elevated for each of the doses compared to
the PBS controls (p < 0.0001). There was a
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Figure 4. Effect of HgCl2 dose on antichromatin
antibodies in female BXSB mice. Female mice
were injected with 40, 4, 0.4 or 0.04 µg HgCl2 in
PBS or with PBS alone for the length of the exper-
iment. Mice were bled at 2-week intervals and
serum antichromatin antibodies determined by
ELISA. Data are expressed as mean ± SE for each
treatment group. 
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Table 5. Disease features in female BXSB after long-term exposure to HgCl2.a
Peripheral blood lymphocyte ﬂow cytometryb
CD3–
Treatment Antichromatin Proteinuria CD4+ CD4+ I-A–
No. (µg HgCl2) Ab mg/dL CD4+ B220+ CD44hi CD62Llo CD11b+
4 PBS 3.74 ± 2.02 32.2 ± 15.2 12.3 ± 1.5 72.1 ± 6.3 15.6 ± 3.6 15.9 ± 5.1 0.7 ± 0.5
4 0.04 4.81 ± 3.26 28.4 ± 9.2 12.7 ± 0.8 73.4 ± 6.9 17.5 ± 5.1 15.2 ± 1.9 0.8 ± 0.3
4 0.40 10.70 ± 4.10‡ 78.4 ± 47.0* 13.4 ± 3.6 74.2 ± 6.4 14.9 ± 3.9 15.8 ± 6.0 1.2 ± 0.5
3 4.00 12.36 ± 4.80‡ 85.3 ± 24.0* 11.6 ± 1.3 74.1 ± 2.9 29.7 ± 3.1# 22.0 ± 3.6 2.3 ± 0.6§
p-Values are from comparison of mercury-treated groups with PBS-treated group.
aMice (8 weeks of age) were injected sc twice per week until 40 weeks of age; values given as mean ± 1SD. bPercent of live gated cells. *p < 0.05. §p < 0.02. ‡p < 0.025. # p < 0.005. strong positive correlation between HgCl2
dosage and kidney mercury levels (R = 0.99).
Discussion
In the present study, exposure of BXSB mice
to mercury was shown to induce accelerated
systemic autoimmunity in both the highly
susceptible male and less susceptible female.
Although we (19) and others (35) have
shown that HgCl2 exposure can induce sys-
temic autoimmunity in other lupus-prone
mice, in each instance the strains tested were
susceptible to HgIA by virtue of their H-2
haplotypes alone. The current findings are
signiﬁcant in that the H-2b haplotype of the
BXSB does not predispose to HgIA (17,18).
Therefore, induction of systemic autoimmu-
nity by HgCl2 exposure clearly implicates
other susceptibility genes, most likely those
related to spontaneous lupus. 
This study also demonstrates that expo-
sure of BXSB mice to either a short course of
high-dose mercury or lower doses over a long
period could trigger systemic autoimmunity.
For female BXSB mice, both the age of initial
exposure and the dose of mercury were
shown to inﬂuence the degree of disease exac-
erbation, particularly for antichromatin anti-
bodies, an autoantibody closely associated
with murine and human lupus (31,36).
Moreover, a transient one-month exposure to
mercury could elicit autoimmunity that per-
sisted for many weeks after cessation of the
xenobiotic and that had several features con-
sistent with idiopathic disease.
Genetic studies show that both MHC and
non-MHC genes can contribute to the expres-
sion of idiopathic systemic autoimmunity
(14). In a previous study (19), comparison of
the responses of MHC identical MRL-+/+
and AKR mice to mercury suggested that
both MHC and non-MHC genes may con-
tribute significantly to mercury toxicity.
However, mercury exposure did not exacer-
bate humoral autoimmunity in the MRL-lpr
mice, suggesting that HgCl2 has little effect
on mice that are already highly susceptible,
or that it acts through the same anti-apop-
totic mechanism as the Fas lpr mutation
(19). In contrast, the present study found
that the highly susceptible Yaa-expressing
male BXSB mice were more sensitive to the
autoimmune-promoting effects of HgCl2
than female BXSB mice, which indicates
that the addition of a strong autoimmune
accelerating gene per se does not preclude
xenobiotic acceleration of autoimmunity.
Taken together with the MRL-Fas lpr
results, this favors the possibility that HgCl2
may promote HgIA by inhibiting the Fas-
induced cell death of autoreactive cells. This
is supported by recent evidence that HgCl2
can protect against Fas-mediated cell death
(37). Because mercury’s effects are thought
to be due primarily to reactivity to sulfhydryl
groups, for which it has the highest binding
(38,39), it is possible that mercury could be
inhibiting cysteine proteases involved in the
downstream events of Fas (40,41). Indeed,
mutations of caspase 10 is one cause of the
autoimmune lymphoproliferation syndrome
in humans, a disease resulting from defective
Fas-mediated apoptosis (42). 
The accelerated autoimmunity in BXSB
mice within the context of an MHC resis-
tant to HgIA (43) suggests that autoimmu-
nity in HgCl2-exposed lupus-prone mice is
due to acceleration of idiopathic disease and
not elicitation of HgIA. In addition, the pre-
dominance of IgG2a and IgG2b subclasses
in the antichromatin Ab response supports
stimulation of a Th1-like cytokine response,
which is more consistent with spontaneous
disease in the BXSB (32). Although gene
knockout studies have revealed that HgIA is
dependent upon interferon-γ (27), disease
expression in nonautoimmune-prone wild-
type mice is associated with a Th2 response
with elevations in IL-4 and autoantibodies of
IgG1 subclass (27,30). The lack of IgG1
antichromatin antibodies in HgCl2-exposed
BXSB mice suggests that mercury is not elic-
iting a polyclonal B-cell response, nor is it
promoting a Th2 response. The acceleration
of autoimmunity by mercury is metal-spe-
cific: Another immune modulatory metal,
nickel, did not accelerate autoimmunity in
NZBWF1 or MRL mice (19). Similar exper-
iments comparing the effects of mercury and
nickel on BXSB mice also revealed that
nickel was ineffective in accelerating autoim-
munity in BXSB mice (data not shown).
These observations suggest that HgCl2 is
acting as a trigger to complement genetic
susceptibility in autoimmune-prone mice
rather than simply inducing HgIA.
Maturation of splenic CD4+ T cells from
naive to activated phenotype, including
increased expression of CD44 and loss of
CD62L (44), has been associated with accel-
erated disease in male BXSB mice (40,44).
Increases in such activated CD4+ T cells
were also observed in HgCl2-exposed female
BXSB mice. This appeared to be dose-
dependent because it was found only in mice
given 4 µg HgCl2. Male BXSB also develop
a strain-speciﬁc peripheral blood monocyto-
sis (45). The cells express Mac-1 (CD11b)
but not I-A, CD3, or B220 (45), and are
thought to contribute to the pathogenesis of
lupus in these mice (46). In contrast,
increased percentages of Mac-1+ cells are not
found in young female BXSB mice (45,46).
HgCl2 exposure increased the percentage of
Mac-1+ cells in female BXSB mice, although
the levels were low and reached statistical
significance only for the group given 4 µg
HgCl2. Whether this small increase in the
percentage of monocytes in the peripheral
blood contributes to autoimmunity is ques-
tionable, especially because mice given 0.4
µg HgCl2 had antichromatin antibodies in
the peripheral circulation in the absence of
any signiﬁcant changes in PBMCs.
The relevance of these observations to
human lupus will require further investiga-
tion because considerable debate exists
regarding the sources and levels of mercury
exposure within the human population (16).
Consequently, few studies have attempted to
equate environmentally relevant mercury
exposure with systemic autoimmune disease
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Figure 5. Representative PAS-stained sections of kidneys from female BXSB mice following long-term expo-
sure to low doses of mercury. (A) PBS alone. (B) 40 µg HgCl2 group. (C) 4 µg HgCl2 group. (D) 0.4 µg HgCl2
alone. Kidney sections were obtained from mice exposed to HgCl2 for a total of 38 weeks, starting at 8 weeks
of age. Glomeruli in (C) show substantial mesangial matrix expansion, thickening of glomerular capillary
tufts, and slight increase in cellularity. Glomeruli in (B) show only minimal changes in the mesangial region.
Magniﬁcation x400.
Table 6. Kidney mercury levels in female BXSB mice continuously exposed to HgCl2.a
Treatment Kidney mercury (ng Hg/g wet weight)
(µg HgCl2) No. Mean ± 1SD Range
PBS 4 12.4 ± 2.5 (10.5–16.0)
0.04 4 76.2 ± 6.0## (71.6–84.2)
0.40 4 662.7 ± 84.7## (569–734)
4.00 3 3643.7 ± 241.0## (3,404–3,886)
p-Values are from comparison of mercury-treated groups with PBS-treated group.
aMice (8 weeks of age) were injected sc twice per week until 46 weeks of age, when they were sacriﬁced to obtain kidneys
for mercury determination. ##p < 0.0001. (47). Most studies have used levels of mer-
cury to elicit autoimmunity in healthy (8)
and autoimmune-prone mice (19) that,
although possibly relevant to human occupa-
tional exposure (16), are greater than envi-
ronmental exposure. 
In attempting to determine the most rel-
evant dose of mercury that would be compa-
rable to environmental exposure, we focused
on mercury levels in the kidney. There are
several reasons for this: The kidney is a
major site of accumulation of mercury in
humans and mice (16,48). Reliable data
exist on human kidney mercury levels with
differing environmental exposures (33,34).
Steady-state levels for mercury in mice are
achieved after less than 4 weeks’ exposure
(49). In addition, the kidney is a major tar-
get organ in human and murine lupus and
may constitute an initial site of tissue dam-
age that leads to systemic exacerbation of
disease (50). Levels of mercury in the kidneys
in nonoccupationally exposed humans cover
a broad range, from undetectable to 2,100 ng
Hg/g wet weight of tissue (33,34), with the
highest levels being found in dental amalgam
bearers [average 433 ng Hg/g wet weight
(34)]. The mercury levels in the kidneys of
mice exposed to 0.4 µg HgCl2/injection fall
within the range found in nonoccupationally
exposed humans. These mice had accelerated
antichromatin antibodies and proteinuria,
which suggests that environmentally relevant
tissue levels of mercury could be associated
with exacerbations of autoimmunity in
genetically susceptible hosts.
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